This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $27.43, moving +0.26% from the previous trading session.
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
by Zacks Equity Research
Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
by Kinjel Shah
AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
by Zacks Equity Research
Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.
GSK Outperforms Industry on Strength in Key Drugs & Vaccines
by Zacks Equity Research
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Pfizer (PFE) closed at $27.63 in the latest trading session, marking a -0.32% move from the prior day.
Pfizer (PFE) to Decrease Stake in Haleon From 32% to 24%
by Zacks Equity Research
Pfizer (PFE) plans to sell some shares of consumer healthcare firm Haleon (HLN), which it owns, to bring down its stake from 32% to 24%.
The Zacks Analyst Blog Highlights Microsoft, Coca-Cola, Accenture, Applied Materials and Pfizer
by Zacks Equity Research
Microsoft, Coca-Cola, Accenture, Applied Materials and Pfizer are included in this Analyst Blog.
Top Research Reports for Microsoft, Coca-Cola & Accenture
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), The Coca-Cola Company (KO) and Accenture plc (ACN).
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More
by Kinjel Shah
AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab
by Zacks Equity Research
Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
Pfizer (PFE) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Pfizer (PFE) stood at $28.22, denoting a +0.75% change from the preceding trading day.
Pfizer's (PFE) Adcetris Meets Survival Goal in Lymphoma Study
by Zacks Equity Research
Pfizer (PFE) plans to seek approval for the eighth indication for Adcetris based on data from the ECHELON-3 study.
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
by Zacks Equity Research
Bayer (BAYRY) acquires exclusive marketing rights for cardiovascular drug acoramidis in Europe from BridgeBio for an upfront payment of $310 million.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer (PFE) Down 0.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pharma Stock Roundup: Pfizer's Velsipity Receives EU Nod, ABBV Gets New CEO & More
by Kinjel Shah
European Commission approves Pfizer's (PFE) Velsipity ulcerative colitis (UC) pill. AbbVie (ABBV) appoints Robert A. Michael as the new CEO.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod
by Zacks Equity Research
The approval for Pfizer's (PFE) Velsipity (etrasimod) is based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12.
A Look at Pharma ETFs After Q4 Earnings
by Sweta Killa
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
by Zacks Equity Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol-Myers (BMY) Q4 Earnings & Sales Beat, Stock Gains
by Zacks Equity Research
Bristol-Myers' (BMY) fourth-quarter 2023 earnings and sales surpass estimates as Reblozyl and Revlimid outperform. Shares rise on the same.
Pharma Stock Roundup: PFE, MRK, NVO & SNY's Q4 Earnings, FDA Updates
by Kinjel Shah
Pfizer (PFE), Merck (MRK), Novartis (NVS), Novo Nordisk (NVO) and Sanofi (SNY) announce fourth-quarter and full-year 2023 results.
Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.